OBEcure Ltd. today began a Phase II clinical trial of its anti-obesity drug Histalean geared to women of childbearing age. 180 women will participate in the trial in Belgium and the Netherlands. The trial will test both the dosage used in the summer 2007 trial and a higher dosage than previously tried.
OBEcure parent company Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) strategy and business development VP Ronit Gross said, "The drug had the fewest side effects, which usually means that the dosage can be increased to get a stronger effect."
Histalean is based on a product that is already sold in Europe for dizziness. The drug showed no statistically significant results in weight loss or the prevention of weight gain in the test population in the large trial last year, but an analysis of the results by segments found that it was effective in women under 50, and in patients taking antipsychotic drugs.
Biolight has two other portfolio companies - Zetiq Technologies Ltd., which has begun sales of its cancer diagnostic kit, and IOptima Ltd., which is undergoing tests for its glaucoma treatment.
Published by Globes [online], Israel business news - www.globes-online.com - on September 8, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008